Exact Sciences holds the cleaner structural position, with the lead spread across growth and profitability. Ionis Pharmaceuticals still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
On growth, the clearer edge sits with Ionis Pharmaceuticals, Inc., while the overall score remains tighter and points the other way.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
The clearest structural overlap shows up in margin trend and revenue growth trajectory.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
The structural gap is limited here, but current pricing still leans against Exact Sciences Corp.
Valuation position uses Forward P/E and peer-relative valuation score where available.
Where EXAS and IONS each sit in their own 4.9-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The current lead is backed by a stronger multi-year growth trajectory.
Ionis Pharmaceuticals, Inc. still looks less cycle-sensitive — that keeps the result from looking completely one-sided.
The lead is built on both growth and profitability — though growth still provides a counterweight.
Break down the EXAS vs IONS comparison across all dimensions with the full interactive tool.
Explore how EXAS and IONS each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.